Eisai to buy TorreyPines' Alzheimer's genetic research
This article was originally published in Scrip
Executive Summary
Eisaihas ended its collaborations with TorreyPines Therapeutics for basic research into the genetic mechanisms of Alzheimer's disease, and is to acquire all data and assets from the programmes. These looked at genes related to late-onset disease (which ended in September 2005) and whole-genome screening to elucidate pathogenesis (this September). Eisai will pay an undisclosed cash amount to the US firm, which is looking to progress several clinical-stage programmes. TorreyPines is also working on in-house gamma secretase modulators for Alzheimer's, for which it is seeking a development partner.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Japan Regulators Kept On Track Despite Pandemic
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports